Peptide modulators of alpha-glucosidase

Journal of Diabetes Investigation

Volumn 6, Issue 6, 2015, Pages 625-631

  Roskar, Irena ^a   Molek, Peter ^a   Vodnik, Miha ^a   Stempelj, Mateja ^a   Strukelj, Borut ^a   Lunder, Mojca ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Maltase glucoamylase; Peptide modulators; Phage display

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; HEPTAPEPTIDE; VOGLIBOSE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SYNTHESIS; ELUTION; ENZYME ACTIVE SITE; ENZYME INHIBITION; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL;

EID: 84945490896     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12358     Document Type: Article

References (40)

1. Mohamed Sham Shihabudeen H, Hansi Priscilla D, Thirumurugan K. Cinnamon extract inhibits alpha-glucosidase activity and dampens postprandial glucose excursion in diabetic rats. Nutr Metab (Lond) 2011; 8: 46.
2. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
3. Hakamata W, Kurihara M, Okuda H, et al. Design and screening strategies for alpha-glucosidase inhibitors based on enzymological information. Curr Top Med Chem 2009; 9: 3-12.
4. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347: 1342-1349.
5. Kwon YI, Vattem DA, Shetty K. Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. Asia Pac J Clin Nutr 2006; 15: 107-118.
6. Asai A, Nakagawa K, Higuchi O, et al. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig 2011; 2: 318-323.
7. Sugihara H, Nagao M, Harada T, et al. Comparison of three alpha-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes. J Diabetes Investig 2014; 5: 206-212.
8. Sim L, Jayakanthan K, Mohan S, et al. New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata. Biochemistry 2010; 49: 443-451.
9. Sim L, Willemsma C, Mohan S, et al. Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains. J Biol Chem 2010; 285: 17763-17770.
10. Quezada-Calvillo R, Robayo-Torres CC, Ao Z, et al. Luminal substrate "brake" on mucosal maltase-glucoamylase activity regulates total rate of starch digestion to glucose. J Pediatr Gastroenterol Nutr 2007; 45: 32-43.
11. Nakamura S, Takahira K, Tanabe G, et al. Homology modeling of human Alpha-Glucosidase catalytic domains and SAR study of salacinol derivatives open. J Med Chem 2012; 2: 50-60.
12. Sim L, Quezada-Calvillo R, Sterchi EE, et al. Human intestinal maltase-glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity. J Mol Biol 2008; 375: 782-792.
13. Moorthy NS, Ramos MJ, Fernandes PA. Studies on alpha-glucosidase inhibitors development: magic molecules for the treatment of carbohydrate mediated diseases. Mini Rev Med Chem 2012; 12: 713-720.
14. Matsubara T. Potential of peptides as inhibitors and mimotopes: selection of carbohydrate-mimetic peptides from phage display libraries. J Nucleic Acids 2012; 2012: 740982.
15. Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display from candidate identification to clinical practice. Mabs-Austin 2014; 6: 73-85.
16. Troitskaya LA, Kodadek T. Peptides as modulators of enzymes and regulatory proteins. Methods 2004; 32: 406-415.
17. Arai K, Tsutsumi H, Mihara H. A monosaccharide-modified peptide phage library for screening of ligands to carbohydrate-binding proteins. Bioorg Med Chem Lett 2013; 23: 4940-4943.
18. Yoshikawa Y, Hirata R, Yasui H, et al. Inhibitory effect of CuSO(4) on alpha-glucosidase activity in ddY mice. Metallomics 2010; 2: 67-73.
19. Oki T, Matsui T, Matsumoto K. Evaluation of alpha-glucosidase inhibition by using an immobilized assay system. Biol Pharm Bull 2000; 23: 1084-1087.
20. Matsui T, Shimada M, Saito N, et al. Alpha-glucosidase inhibition assay in an enzyme-immobilized amino-microplate. Anal Sci 2009; 25: 559-562.
21. Huang J, Ru B, Zhu P, et al. MimoDB 2.0: a mimotope database and beyond. Nucleic Acids Res 2012; 40: D271-D277.
22. Vodnik M, Zager U, Strukelj B, et al. Phage display: selecting straws instead of a needle from a haystack. Molecules 2011; 16: 790-817.
23. Huang J, Ru B, Li S, et al. SAROTUP: scanner and reporter of target-unrelated peptides. J Biomed Biotechnol 2010; 2010: 101932.
24. Suresh Babu K, Tiwari AK, Srinivas PV, et al. Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson. Bioorg Med Chem Lett 2004; 14: 3841-3845.
25. Ohta T, Sasaki S, Oohori T, et al. Alpha-glucosidase inhibitory activity of a 70% methanol extract from ezoishige (Pelvetia babingtonii de Toni) and its effect on the elevation of blood glucose level in rats. Biosci Biotechnol Biochem 2002; 66: 1552-1554.
26. Kim KY, Nam KA, Kurihara H, et al. Potent alpha-glucosidase inhibitors purified from the red alga Grateloupia elliptica. Phytochemistry 2008; 69: 2820-2825.
27. Eichler J, Lucka AW, Pinilla C, et al. Novel alpha-glucosidase inhibitors identified using multiple cyclic peptide combinatorial libraries. Mol Divers 1996; 1: 233-240.
28. Oki T, Matsui T, Osajima Y. Inhibitory effect of alpha-glucosidase inhibitors varies according to its origin. J Agric Food Chem 1999; 47: 550-553.
29. Oku T, Tanabe K, Ogawa S, et al. Similarity of hydrolyzing activity of human and rat small intestinal disaccharidases. Clin Exp Gastroenterol 2011; 4: 155-161.
30. Lunder M, Bratkovic T, Kreft S, et al. Peptide inhibitor of pancreatic lipase selected by phage display using different elution strategies. J Lipid Res 2005; 46: 1512-1516.
31. Mennuni C, Santini C, Dotta F, et al. Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. J Autoimmun 1996; 9: 431-436.
32. Smith GP, Petrenko VA. Phage display. Chem Rev 1997; 97: 391-410.
33. Gaser D, Štrukelj B, Bratkovič T, et al. Cross-affinity of peptide ligands selected from phage display library against pancreatic Phospholipase A2 and Ammodytoxin C. Acta Chim Slov 2009; 56: 712-717.
34. Denisova GF, Denisov DA, Bramson JL. Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design. Immunome Res 2010; 6(Suppl 2): S6.
35. Lee BH, Eskandari R, Jones K, et al. Modulation of starch digestion for slow glucose release through "toggling" of activities of mucosal alpha-glucosidases. J Biol Chem 2012; 287: 31929-31938.
36. Ren L, Cao X, Geng P, et al. Study of the inhibition of two human maltase-glucoamylases catalytic domains by different alpha-glucosidase inhibitors. Carbohydr Res 2011; 346: 2688-2692.
37. Johnson MA, Pinto BM. Structural and functional studies of Peptide-carbohydrate mimicry. Top Curr Chem 2008; 273: 55-116.
38. Olmez EO, Akbulut BS. Protein-Peptide Interactions Revolutionize Drug Development. InTech, Rijeka, Croatia, 2012.
39. Tsuchimochi W, Ueno H, Yamashita E, et al. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J 2014; 62: 13-20.
40. Fukuda-Tsuru S, Anabuki J, Abe Y, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 2012; 696: 194-202.